北京人起源
发表于 2025-3-28 18:15:53
, despite their generally advanced stage at presentation. In general, HNSCCs develop in precancerous mucosal changes, and the apparent lack of precancerous HPV+ve mucosal changes is therefore remarkable. In this Chapter, head and neck carcinogenesis is discussed and the molecular differences between HPV+ve and HPV-ve tumors are outlined.
RALES
发表于 2025-3-28 21:52:55
http://reply.papertrans.cn/43/4204/420307/420307_42.png
昏睡中
发表于 2025-3-29 01:14:54
http://reply.papertrans.cn/43/4204/420307/420307_43.png
反省
发表于 2025-3-29 04:14:57
http://reply.papertrans.cn/43/4204/420307/420307_44.png
Confound
发表于 2025-3-29 08:38:36
http://reply.papertrans.cn/43/4204/420307/420307_45.png
宏伟
发表于 2025-3-29 15:26:17
http://reply.papertrans.cn/43/4204/420307/420307_46.png
HERTZ
发表于 2025-3-29 17:46:28
http://reply.papertrans.cn/43/4204/420307/420307_47.png
拍下盗公款
发表于 2025-3-29 23:40:22
Variation of HPV Subtypes with Focus on HPV-Infection and Cancer in the Head and Neck Regionn subtypes are essentially heterogeneous in efficacy triggering neoplastic transformation and cancer development. This could explain differences in the clinical course of HPV-driven head and neck cancer.
MOT
发表于 2025-3-30 00:09:56
Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCCHPV in the R/M situation are still scarce. Due to the rising incidence of HPV-associated cancers, the number of R/M HPV+ carcinomas is also expected to rise. This chapter therefore aims to give an overview of the current knowledge concerning the role of HPV as a prognostic and predictive marker in recurrent or metastatic HNSCC.
察觉
发表于 2025-3-30 07:00:51
Should We De-escalate the Treatment for HPV-Positive Tumors?clinical reports and lack of data of prospective trials not mature for routine clinical decision making in 2016. Independent of the currently lacking evidence for HPV-dependent treatment de-escalation, there are some relevant arguments to address this question in ongoing and future trials.